Furthermore, PRMT1 knockdown downregulates TGF‐β1 and phospho‐Smad2/3, while its overexpression has the opposite effect, confirming that PRMT1 facilitates EMT in liver cancer via the TGF‐β1/Smad pathway and highlighting its therapeutic potential [88]. Here, PRMT1 is linked to liver cancer.